Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P12755
UPID:
SKI_HUMAN
Alternative names:
Proto-oncogene c-Ski
Alternative UPACC:
P12755; Q5SYT7
Background:
The Ski oncogene, also known as Proto-oncogene c-Ski, plays a crucial role in the differentiation of skeletal muscle cells and acts as a repressor of TGF-beta signaling. This protein is pivotal in cellular processes, influencing not only muscle cell fate but also cellular responses to growth factors.
Therapeutic significance:
Linked to Shprintzen-Goldberg craniosynostosis syndrome, a condition marked by skeletal, cardiovascular abnormalities, and developmental challenges, the Ski oncogene's study offers insights into potential therapeutic avenues. Understanding the role of Ski oncogene could open doors to potential therapeutic strategies.